Programs Pipeline

Sirona Biochem specializes in the development of carbohydrate-based molecules. While carbohydrate-based molecules offer immense commercial potential, we are focused on advancing three programs – therapeutics, cosmetic agents and biological ingredients.  Our two most advanced programs include a diabetes treatment candidate and a cosmetic skin lightening agent. 

Our sodium glucose co-transporter (SGLT) inhibitor for diabetes, achieved positive preclinical results. In a head-to-head preclinical study, Sirona Biochem’s SGLT inhibitor performed better than Johnson and Johnson’s canagliflozin (Invokana™), which was given FDA market approval in the U.S. (March 2013) and is being considered for market approval in Europe.  We have begun partnering discussions to review options for the outlicensing of our SGLT inhibitor.  A pharmaceutical partner would handle the downstream clinical and commercial needs of our program.

Recognized for the scientific innovation at our laboratory in France, the French government awarded our team an innovation grant worth CDN$1.9 Million to develop our cosmetic skin lightener program to a commercial ready stage.  Several efficacy and stability studies have been completed with results showing superiority over popular commercial products.  Further toxicity studies are underway.

Sirona Biochem’s proprietary chemistry technology has relevance in many therapeutic, cosmetic and biological areas where the potential for development is high.  In addition to the diabetesskin lightener, anti-aging and biological ingredients programs, the company is exploring development of the following:

Cancer Vaccine Antigen

Our scientists have formulated a Tn antigen that could be valuable as a key component for the development of a cancer vaccine.

In healthy individuals, certain antigens are suppressed by the body’s immune system. In patients with cancer, research has shown that a higher presence of Tn antigens on the cell surface are linked to higher malignancy and growth. These antigens promote cancer cell adhesion and thus are linked to cancer metastases, allowing cancer to spread from one organ to another.  By producing a synthetic version of the Tn antigen it can be used in a vaccine that can potentially trigger the immune system to recognize it as a foreign substance. Previous attempts by scientists to develop a vaccine with the Tn antigen have been unsuccessful due to the chemistry challenges in stabilizing the molecule.

Sirona Biochem TFChem Laboratory

Sirona Biochem TFChem Laboratory

Product Development

While carbohydrate-based molecules offer immense commercial potential, we are focusing on three programs at this time.